产品
编 号：F235568
分子式：C21H20N2O2
分子量：332.4
分子式：C21H20N2O2
分子量：332.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1883528-69-5
产品详情
生物活性：
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM.
体内研究：
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice.Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice.Animal Model:C57BL/6J mice.
Dosage:100 mg/kg.
Administration:I.G. (gavage) once daily for 7 days.
Result:Significantly decreased the plasma SM levels compared with vehicle group.
Animal Model:ApoE KO mice (eight-week-old).
Dosage:12.5 or 40 mg/kg.
Administration:I.G. (gavage) once daily.
Result:The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group.
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM.
体内研究：
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice.Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice.Animal Model:C57BL/6J mice.
Dosage:100 mg/kg.
Administration:I.G. (gavage) once daily for 7 days.
Result:Significantly decreased the plasma SM levels compared with vehicle group.
Animal Model:ApoE KO mice (eight-week-old).
Dosage:12.5 or 40 mg/kg.
Administration:I.G. (gavage) once daily.
Result:The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备